AnalysisEncouraging signs in a tough year for Euro...Continuing geopolitical uncertainty has perpetuated volatility in global markets, exacerbated by higher inflation and interest rates. The impact has left the biotech market in a limbo as investors eschew … more ➔
New genomic techniquesPlant breeding innovation reloaded?The European Court of Justice ruling from 2018 which put the latest breeding methods under the EU GMO legislation was a huge pushback for plant breeding innovation in the EU. With the proposal for a … more ➔
Analyst comment‘Older & Fatter’ megatrend...Stock markets love investment concepts, calling the robust ones ‘megatrends’. Golden ageing is one such megatrend banking on the fact that business can extract more from people living longer. Such … more ➔
'Older & Fatter' megatrend i...Stock markets love investment concepts, calling the robust ones ‘megatrends’. Golden ageing is one such megatrend banking on the fact that business can extract more from people living longer. Such … more ➔
StatementBuilding a new industry and medicine thank... Biotechnology is helping us tackle challenges such as emerging diseases, the impact of ageing in healthcare, population growth, climate change, and the green transition of the economy. Precision medicines, … more ➔
Analyst commentBiotech companies challenged in times of i...Inflation has rebounded with a vengeance from its pandemic-induced recession lows. The US headline inflation rate surged to levels not seen since Ronald Reagan’s presidency, while the Eurozone’s … more ➔
bioeconomyBuilding on the successes of Europe’... The bioeconomy can be a major driver in bringing circularity, sustainability and competitive production to Europe as it aims towards becoming climate-neutral and more self-sufficient. more ➔
EMAConflict of interest?In 2016, PharmaMar filed a European marketing authorisation application for Aplidin as a treatment for patients with multiple myeloma. After the European Medicines Agency rejected the MAA twice, which … more ➔
Analyst commentBiotech funding environment calls for more...From its all-time high in August 2021 the largest and most important index for the biotech industry also in Europe (NBI) lost around 25%. After a period of excessive capital inflows, money is much harder … more ➔
